1. Home
  2. NAMSW vs CHUY Comparison

NAMSW vs CHUY Comparison

Compare NAMSW & CHUY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • CHUY
  • Stock Information
  • Founded
  • NAMSW N/A
  • CHUY 1982
  • Country
  • NAMSW Netherlands
  • CHUY United States
  • Employees
  • NAMSW 29
  • CHUY N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • CHUY Restaurants
  • Sector
  • NAMSW Health Care
  • CHUY Consumer Discretionary
  • Exchange
  • NAMSW Nasdaq
  • CHUY Nasdaq
  • Market Cap
  • NAMSW N/A
  • CHUY N/A
  • IPO Year
  • NAMSW N/A
  • CHUY 2012
  • Fundamental
  • Price
  • NAMSW $9.45
  • CHUY $25.35
  • Analyst Decision
  • NAMSW
  • CHUY Buy
  • Analyst Count
  • NAMSW 0
  • CHUY 8
  • Target Price
  • NAMSW N/A
  • CHUY $35.75
  • AVG Volume (30 Days)
  • NAMSW N/A
  • CHUY 168.9K
  • Earning Date
  • NAMSW N/A
  • CHUY 08-01-2024
  • Dividend Yield
  • NAMSW N/A
  • CHUY N/A
  • EPS Growth
  • NAMSW N/A
  • CHUY 33.86
  • EPS
  • NAMSW N/A
  • CHUY 1.70
  • Revenue
  • NAMSW N/A
  • CHUY $459,276,000.00
  • Revenue This Year
  • NAMSW N/A
  • CHUY $3.21
  • Revenue Next Year
  • NAMSW N/A
  • CHUY $10.19
  • P/E Ratio
  • NAMSW N/A
  • CHUY $14.45
  • Revenue Growth
  • NAMSW N/A
  • CHUY 5.77
  • 52 Week Low
  • NAMSW N/A
  • CHUY $22.52
  • 52 Week High
  • NAMSW N/A
  • CHUY $42.89
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 50.58
  • CHUY 50.71
  • Support Level
  • NAMSW $9.40
  • CHUY $22.52
  • Resistance Level
  • NAMSW $10.14
  • CHUY $25.15
  • Average True Range (ATR)
  • NAMSW 0.48
  • CHUY 0.68
  • MACD
  • NAMSW 0.06
  • CHUY 0.07
  • Stochastic Oscillator
  • NAMSW 29.67
  • CHUY 79.49

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: